XUANZHUBIO-B (02575) saw its shares rise more than 12% in afternoon trading. At the time of writing, the stock was up 4.97%, trading at HK$32.54 with a turnover of HK$80.7147 million. The company announced it has received a formal filing notice from the China Securities Regulatory Commission, completing the conversion of 357 million non-tradable shares held by six shareholders into 357 million H-shares. Upon completion, XUANZHUBIO-B's tradable share base is expected to expand significantly, leading to a fundamental improvement in liquidity. Notably, on April 9, XUANZHUBIO-B announced it had entered into a licensing and supply agreement with Boston Oncology for two of its self-developed oncology drugs, piroplinib (Xuan Yue Ning®) and diroac (Xuan Fei Ning®). Under the agreement, the company granted exclusive commercialization rights in 21 countries and regions across the Middle East and North Africa. XUANZHUBIO-B is expected to receive an upfront payment and cumulative milestone payments exceeding $100 million, in addition to royalties based on sales.